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INTRODUCTION 
Parasite	 invasions	 are	 one	 of	 the	main	 diag-
nosed	 pathologies	 of	 European	 bison	 (Krzysiak	
et al.,	 2015).	 If	 a	 poorly	 effective	 drug	 is	 used	
or	 if	 the	 efficient	 medication	 is	 underdosed,	
development	 of	 drug	 resistance	 occurs	 (Cernea	
et al.,	2015,	Woodbury	et al.,	2011).	In	order	to	be	
able	 to	 control	 these	pathologies,	 it	 is	 important	
to	 monitor	 the	 dewormings	 and	 assess	 the	
effectiveness	 of	 the	 active	 ingredients	 used	 as	
antiparasitic	 medication	 (Cernea	 et al.,	 2005,	
Demiaszkiewicz	 et al.,	 2010,	 Krzysiak	 et al., 
2015).	In	this	context,	the	present	paper	is	aimed	
to	 evaluate	 the	 efficacy	 of	 benzimidazole	 and	
tetrahydropyrimidine	anthelmintic	agents	against	
the	 intestinal	 nematodes	 of	 the	 European	 bison	
(Bison bonasus).	
MATERIALS AND METHODS An in vitro	 study	 was	 conducted	 to	 assess	
the	efficacy	of	 four	anthelmintic	drugs	against	 in	
digestive	strongylidosis	in	bison	between	October	
2016	 and	May	 2017.	 The	 ovicidal	 and	 larvicidal	
effects	 of	 benzimidazole	derivatives,	 albendazole	
(ABZ),	 mebendazole	 (MBZ)	 and	 thiabendazole 
(TBZ)	 and	 larvicidal	 effect	 of	 pyrantel	 (PYR), a	
tetrahydropyrimidine	 derivative	 were	 evaluated.	
The	gastrointestinal	parasites	were	obtained	from	
faecal	 samples,	 harvested	 from	 European	 bisons	
living	 in	 Slivuţ	 Reservation,	 Hunedoara	 County	
and	 Armeniş	 Reservation	 Caraş-Severin	 County,	
Romania,	 as	 well	 as	 Avesta	 Visentpark,	 Sweden.	
The	bisons	have	not	been	dewormed	prior	to	the	
collection	 of	 stool	 samples.	 Strongyle eggs were	
collected	 by	 flotation	methods and two	 types	 of	
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ABSTRACT
The	present	 study	was	aimed	 to	evaluate	 the	efficacy	of	 anthelmintic	 agents	against	 intestinal	nematodes	
found	in	European	bison.	It	was	performed	between	October	2016	and	May	2017,	using	Egg	Hatch	Assay	(EHA)	
and	Larval	Development	Assay	(LDA).	The	parasites	were	obtained	from	faecal	samples,	harvested	from	bisons	in	
Romania	and	Sweden.	The	efficacy	of	albendazole	(ABZ),	mebendazole	(MBZ)	thiabendazole	(TBZ)	and	pyrantel	
(PYR)	was	tested.	In	EHA,	the	maximum	efficacy	was	observed	in	MBZ	(EC
50
	=	-	0.227	µg/ml),	and	then	TBZ	(EC
50
 
=	 -	 0.2228).	 ABZ	 had	 a	 weaker	 result,	 EC
50	
being	 0.326	 µg/ml.	 All	 tested	 benzimidazoles	 registered	 hatching	
percentages	below	50%,	reflecting	the	lack	of	parasitic	resistance.	MIC	obtained	in	the	LDA	tests	were	0.2144	µg/
ml	for	TBZ,	0.2792	µg/ml	for	PYR,	0.5429	µg/ml	for	MBZ,	while	ABZ	came	last	(MIC	=	0.8187	µg/ml).	The	in vitro 
tests	proved	the	antiparasitic	molecules	efficacy	against	bisons	nematode	population	and	a	limited	risk	of	inducing	
resistance	phenomena.
Keywords: benzimidazoles, bison, pharmacodynamics, pyrantel
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tests	were	performed:	Egg	Hatch	Assay	(EHA)	and	
Larval	Development	Assay	(LDA).	The	techniques	
were	 performed	 within	 the	 Pharmacovigilance	
Laboratory	 of	 Cluj-Napoca	 Veterinary	 Medicine	
Faculty	as	per	protocol	of		Le	Jambre	(1978).	
The	 total	 number	 of	 eggs	 per	 milliliter	 was	
determined	applying	the	formula: 
Eggs/ml = (1000 x no. eggs per 50µl) / 50
Interpretation	 of	 EHA	 results	 was	 obtained	
by	 comparing	 them	 to	 the	 results	 obtained	 at	
a	 reference	 concentration	 of	 0.15	 mcg/ml,	 as	
strongyle populations	 in	 which	 eggs	 hatch	 in	 a	
percent	 of	 50	 or	 above	 are	 normally	 considered	
resistant.	As	initial	solutions,	serial	dilutions	from	
500	mcg	 to	 0.98	mcg	 active	 ingredient/ml	were	
used.	2	ml	well	plates	were	used	for	conducting	in 
vitro	bioassays.	 In	each	of	 the	 first	10	wells,	790	
μl	of	distilled	water,	200	µl	of	egg	suspension	and	
10	µl	of	each	diluted	drug	solutions	were	placed,	
obtaining	 the	 final	 solutions,	 from	 5.0	 to	 0.0098	
mcg	active	ingredient/ml.	Two	controls	were	used,	M
1
	 control	 consisted	 of	 200	 µl	 egg	 suspension	
and	800	µl	distilled	water	and	a	 the	second	one,	M
2
,	consisting	of	790µl	distilled	water,	200	µl	egg	
suspension	 and	 10	 µl	 of	 HCl	 solution.	 After	 24	
hours	 in	 the	 thermostat	 at	 27ºC,	 samples	 were	
asessed	 by	 counting	 both	 the	 embryonated	 and	
unembryonated	eggs	as	well	as	the	hatched	larvae.
The	egg	hatching	percentage	was	determined	
applying	the	formula:
Egg hatching % = [(EE + L1 ) / ( UE + EE + L1)] x 100
where	EE	represents	the	embryonated eggs,	L
1
	re-
presents	larvae	L
1
	and	UE	stands	for	unembryo-
nated eggs	 (Coles	et al.,	1992,	Le	 Jambre	et al, 
1978). 
For	Larval	development	assay	(LDA),	we	tested	
the	 MIC	 after	 keeping	 the	 exogenous	 parasitic	
forms	in	contact	with	the	antiparasitic	medication	
for	 14	 days,	 at	 a	 constant	 temperature	 of	 27ºC.	
Larval	 development	 percentage	 was	 calculated	
applying	the	formula:	
Larval development % = [(L3  / ( UE + L3)] x 100
where	L
3
	represents	the	number	of	L
3
	 larvae	and	
UE	stands	for	unembryonated eggs.	
The	 results	obtained	were	 statistically	 inter-
preted	 using	 a	 PC	 software	 especially	 created	
for	 this	 type	 of	 calculations,	 called	 Anthelmintic	
Resistance	Program	(ARP™),	obtaining	and	corre-
lating	 the	 following	 parameters	 –	 egg	 hatching	
percentage,	 larval	 development	 percentage,	
regression	line	and	and	its	equation	(Y	parameters),	
the	mean	concentration	that	inhibited	hatching	in	
50%	of	 the	 eggs	 (EC
50
)	 and	minimum	 inhibitory	
concentration	(MIC)	(Cernea	et al,.	2010,	Coles	et 
al.,	1992).
RESULTS AND DISCUSSIONS
In	EHA,	for	TBZ	active	ingredient,	a	substantial	
reduction	 of	 first	 stage	 larvae	 was	 observed,	
compared	to	the	number	of	eggs,	with	14500	eggs,	
respectively	4500	L
1
	larvae.	These	were	identified	
only	in	the	case	of	0.3125	mcg/ml	dilution	and	in	
the	control	samples.	The	low	hatching	percentage	
determined,	through	statistical	analysis,	led	to	the	
calculation	of	a	negative	EC
50
, i.e.	–	0.2228	mcg/ml.	
To	be	able	to	get	pharmacologically	interpretable	
data	with	positive	values	of	EC
50
,	 serial	dilutions	
lower	 than	 0.0098	 mcg/ml	 should	 have	 been	
used.	 At	 the	 reference	 concentration	 (0.15	mcg/
ml),	 the	 hatching	 percentage	 was	 null	 by	 direct	
determination	and,	by	mathematical	analysis,	we	
obtained	a	value	of	-	8.7858	(Tab.	1).	
For	 this	 molecule,	 the	 regression	 line	 had	
a	 negative	 trend,	 with	 an	 Y
max
	 of	 -	 773.34	 mcg/
ml,	 prooving	 that	 the	 isolated	 bison	 parasite	
populations	 only	 possess	 a	 limited	 capacity	 to	
adapt	to	TBZ	based	medication.	
EHA	 tests	 on	 albendazole showed	 different	
hatching percentages	 depending	 on	 the	
concentrations	 used.	 Twenty-four	 hours	 after	
incubation,	 the	 ratio	 between	 the	 total	 number	
of	 eggs	 and	 the	 total	 number	 of	 L
1
 larvae,	 was	
23500/6500.	
Hatching percentage	at	the	reference	concen-
tration	was	33.33%,	below	the	maximum	allowed 
(50%).	 Mathematical	 analysis	 of	 the	 ABZ	 data	
showed	 a	 EC
50
	 of	 0.3261	 mcg/ml,	 the	 hatching	
percentage	 at	 the	 reference	 concentration	 being	
33.81	mcg/ml (Tab.	1).
High	 values	 were	 also	 recorded	 at	 the	
parameters	„a”	and	„b”	which	determined		positive	
values	for	Y	parameter,	with	a	maximum	of	479.19	
mc/ml.	As	a	result,	the	strongyle	population	has	a	
high	capacity	to	adapt	in	the	future	to	ABZ-based	
anthelmintic	products.
CĂTANĂ et al
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Tab. 1.	Egg	hatch	assay	results	for	thiabendazole	and	albendazole	
Sample
A.i.	conc.
(mcg/
ml)
TBZ ABZ
No.	of	
eggs
L1
Egg	
hatching	
%
Regression	
line 
equation
No.of	
eggs
L1
Egg	
hatching	
%
Regression	
line 
equation
1 5.0000 1000 0 0.00 -773.34 1000 1000 50.00 479.19
2 2.5000 1000 0 0.00 -379.24 1000 0 0.00 249.62
3 1.2500 1000 0 0.00 -182.19 1000 0 0.00 134.83
4 0.6250 1000 0 0.00 -83.67 4000 0 0.00 77.43
5 0.3125 1000 4000 80.00 -34.40 5000 1000 16.67 48.74
6 0.1563 2000 0 0.00 -9.78 2000 1000 33.33 34.39
7 0.0781 1000 0 0.00 2.55 2000 1000 33.33 27.21
8 0.0391 2000 0 0.00 8.70 1000 1000 50.00 23.63
9 0.0195 3000 0 0.00 11.79 3000 1000 25.00 21.83
10 0.0098 1000 0 0.00 13.32 1000 0 0.00 20.94
HCl	+	
H2O
0.0000 500 500 50.00 14.86 2500 500 16.67 20.04
Total 14500 4500 23500 6500
Parameters Hatching	%	ref.
EC
50
	(mcg/
ml)
Parameters
Hatching	
%	ref.
EC
50
	(mcg/ml)
a -157.64 -8.7858 -0.2228 a 91.83 33.8100 0.3261
b 14.86 b 20.04
Note:	A.i.	conc.	=	active	ingredient	concentration,		EC
50
=	mean	concentrations	that	inhibited	hatching	in	50%	of	the	eggs,	Hatching	%	ref.	=		
Hatching	percentage	at	reference	concentration	of	0.15	mcg/ml
Tab. 2.	Egg	hatch	assay	results	for	mebendazole	
Sample
A.i.	conc.
(mcg/ml)
MBZ
No.	of	eggs L1 Egg	hatching	%
Regression	
line	equation
1 5.0000 1000 0 0.00 -860.66
2 2.5000 4000 0 0.00 -425.19
3 1.2500 1000 0 0.00 -207.45
4 0.6250 1000 0 0.00 -98.58
5 0.3125 5000 0 0.00 -44.14
6 0.1563 1000 0 0.00 -16.94
7 0.0781 2000 0 0.00 -3.31
8 0.0391 1000 100 9.09 3.48
9 0.0195 1000 0 0.00 6.89
10 0.0098 1000 0 0.00 8.58
HCl	+	H2O 0.0000 1000 1000 50.00 10.29
Total 19000 1100
Parameters EC
50
	(mcg/ml) Hatching	%	ref.
a -174.19 -0.2270 -15.8300
b 10.29
Note:	A.i.	conc.	=	active	ingredient	concentration,	EC
50
=	mean	concentrations	that	inhibited	hatching	in	50%	of	the	eggs,	Hatching	%	ref.	=		
Hatching	percentage	at	reference	concentration	of	0.15	mcg/ml.
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It	 should	 be	 noted	 that in	 the	 case	 of	 ABZ,	
in vivo	 results	may	 be	 very	 different	 from	 those	
obtained	 in vitro,	 due	 to	 its	 enterohepatic	
recirculation,	which	allows	for	the	appearance	of	
active	 metabolites	 that	 will	 repeatedly	 exercise	
their	 anthelmintic	 action.	 This	 phenomenon	 is	
known	 to	 be	 a	 drawback	 of	 the	 in vitro	 tests,	
compared	to	 the	 in vivo	 faecal	egg	reduction	test 
(Cernea	et al., 2006).	As	a	result,	it	can	be	concluded	
that	for	albendazole	EHA	test	results,	highlight	the	
ovocidal	action.
The	MBZ	effect	on	strongyl	eggs	was	highlighted	
by	the	fact	that,	24	hours	after	incubation,	a	very	
small	 number	 of	 L
1
 larvae	 (1100)	 was	 found	
compared	 to	unhatched	eggs	 (19000).	At	0.0391	
mcg/ml	 concentration,	 a	 hatching	 percentage	 of 
9.09%	was	noticed,	while	 for	other	dilutions	 the	
hatching	percentage	was	null	(Tab.	2).
In	 the	 control	 samples,	 the	average	hatching	
percentage	was	50%	which,	by	statistical	analysis,	
determined	 a	 EC
50
	 of	 -	 0.2270	 mcg/ml	 with	 a	
hatching	 percentage	 of	 	 -5.83%.	 As	with	 TBZ,	 in	
order	to	obtain	positive	values	for	EC
50
,	the	serial	
dilutions	should	be	higher	than	5	mcg/ml.
The	 increased	efficacy	of	MBZ	is	also	proven	
by	 the	 regression	 line	 equation,	 whose	 Y
max
 
parameter	 was	 -	 860.66,	 being	 the	 lowest	 value	
of	the	tested benzimidazoles.	For	LDA	test,	in	case	
of	 thiabendazole,	 the	ratio	between	 the	 total	egg 
number	+	 L
1
	 larvae	+	 L
2
	 larvae	 to	 L
3
	 larvae,	was	
11500/7500,	 showing	 a	 different	 development	
percentage,	depending	on	the	used	concentrations.	
At	 the	maximum	concentration	of	5	mcg/ml,	 the	
development	 percentage	 was	 null,	 while	 at	 2.5	
mcg/ml	the	percentage	was	75.	
The	maximum	larval	development	percentage	
was	recorded	for		0.3125	mcg/ml	concentration.
In	 control	 samples,	 average	 development	
percentage	was	50%	and,	dependant	on	this	value,	
mathematical	 analysis	 determined	 a	 minimum	
inhibitory	concentration	(MIC)	of	0.2144	mcg/ml.	
Additionally,	the	value	of	the	„a”	parameter	being	
a	negative	one	(-	148.36),	allowed	the	calculation	
of	the	regression	line	equation,	whose	maximum	Y	
parameter	had	the	value	of	-707.48.	Therefore,	the	
efficacy	of	TBZ	on	this	nematode	population	was	
also	demonstrated	by	the	LDA	tests	(Tab.	3).	
Tab. 3.	Larval	development	assay		results	for	thiabendazole	and	albendazole
A.i.	
conc.	
(mcg/
ml)
Sample	
no.
TBZ ABZ
Eggs
+	L1
+	L2
L3
Larval	
develop-
ment	%
Regression	
line 
equation
Eggs
+	L1
+	L2
L3
Larval	
develop-
ment	%
Regression	
line 
equation
5.0000 1 1000 0 0.00 -707.48 2000 0 0.00 -230.05
2.5000 2 1000 3000 75.00 -336.58 6000 0 0.00 -92.53
1.2500 3 2000 0 0.00 -151.13 3000 0 0.00 -23.76
0.6250 4 1000 1000 50.00 -58.41 1000 0 0.00 10.62
0.3125 5 0 1000 100.00 -12.04 2000 1000 33.33 27.81
0.1563 6 1000 0 0.00 11.13 0 1000 100.00 36.40
0.0781 7 1000 0 0.00 22.73 2000 1000 33.33 40.70
0.0391 8 1000 0 0.00 28.52 3000 0 0.00 42.85
0.0195 9 2000 1000 33.33 31.43 3000 2000 40.00 43.93
0.0098 10 1000 1000 50.00 32.87 0 2000 100.00 44.46
0.0000
H2O	
+HCl
500 500 50.00 34.32 3000 1000 25.00 45.00
Total 11500 7500 25000 8000
MIC	-	mcg/ml Parameters MIC	-	mcg/ml Parameters
0.2144
a -148.36
0.8187
a -55.01
b 34.32 b 45
Note:	A.i.	conc.	=	active	ingredient	concentration,	MIC	=	Minimum	inhibitory	concentration
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Notwithstanding	the	 fact	 that	 in vitro	 testing	
may	 not	 reveal	 ABZ	 active	 metabolites	 activity	
and	effects,	it	can	be	said	that	results	obtained	in	
the	 LDA	 test	 have	 shown	 a	 good	 efficacy	 of	 this	
benzimidazole. 
After	 14	 days	 of	 incubation,	 the	 total	 L
3
 
larvae	number	was	8000,	compared	 to	 the	other	
exogenous forms, which	were	25000.
The	 first	 L
3
	 larvae	 identified	 were	 observed	
at	 0.3125	 mcg/ml	 dilution,	 the	 development	
percentage	 being	 33%.	 Maximum	 rates	 of	
development	were	registered	for	0.1563	mcg/ml,	
and	0.0098	mcg/ml	dilutions.	Mean	development	
percentage	 on	 control	 samples	 was	 25%	 and	
the	 mathematical	 calculations	 highlighted	 an	
albendazole	 MIC	 of	 0.8187	 mcg/ml.	 Regression	
line	 tendency	 was	 negative,	 with	 a	 value	 of	 the	
maximum	Y	parameter	of	-230.05	mcg/ml.	
Results	 obtained	 by	 LDA	 when	 testing	 me-
bendazole showed	that	 total	number	of	 infesting	
larvae	 was	 6500,	 compared	 to	 other	 exogenous	
forms,	which	were	17500.	At	 the	maximum	con-
centration	 (5	 mcg/ml),	 development percentage	
was	33.33%.
The	 maximum	 development	 percentage	
(100%)	 was	 registered	 for	 0.0781	 mcg/ml	 con-
centration.	In	control	samples,	mean	development	
percentage	was	50%,	determining	for	MBZ	a	MIC	
of	0.5429	mcg/ml.	Regression	line	equation	had	a	
downward	trend,	maximum	value	of	Y	parameter	
being	-276.47	mcg/ml	(Tab.	4).	
In	 the	 case	 of	 pyrantel	 (PYR),	 the	 larvicidal	
effect	was	 proven	 by	 the	 fact	 that	 null	 values	 of	
larval	developmental	percentage	were	obtained	at	
four	different	concentrations.	
Also,	a	25%	larval	development	was	calculated	
for	 1.25	mcg/ml	 concentration	 and	 100%	 larval	
development	for	0.625	mcg/ml	and	0.0098	mcg/
ml	concentrations.	
Mean	 larval	 development	 percentage	 for	
control	samples	was	50%.	The	first	stage	3	larvae	
were	 identified	at	 the	2.5	mcg/ml	concentration,	
thus	 allowing,	 by	 global	 mathematical	 analysis,	
obtaining	 of	 a	 0.2792	 mcg/ml	 MIC.	 For	 PYR,	
regression	 line	 equation	 showed	 the	 maximum	
y	 parameter	 with	 the	 lowest	 value	 obtained	
in	 the	 LDA	 tests,	 respectively	 -767.12	 mcg/ml. 
Comparative	analysis	of	the	predictive	adaptability	
Tab. 4.	Larval	development	assay		results	for	mebendazole	and	pyrantel	
A.i.	
conc.	
(mcg/
ml)
Sample	
no.
MBZ PYR
Eggs
+	L1
+	L2
L3
Larval	
develop-
ment	%
Regression	
line 
equation
Eggs
+	L1
+	L2
L3
Larval	
develop_
ment	%
Regression	
line	equation
5.0000 1 2000 1000 33.33 -276.47 2000 0 0.00 -767.12
2.5000 2 1000 0 0.00 -118.60 2000 1000 33.33 -359.55
1.2500 3 3000 0 0.00 -39.66 3000 1000 25.00 -155.76
0.6250 4 1000 0 0.00 -0.19 0 2000 100.00 -53.86
0.3125 5 3000 0 0.00 19.55 1000 0 0.00 -2.92
0.1563 6 3000 0 0.00 29.41 2000 0 0.00 22.55
0.0781 7 0 1000 100.00 34.35 1000 1000 50.00 35.30
0.0391 8 1000 0 0.00 36.81 2000 0 0.00 41.66
0.0195 9 1000 2000 66.67 38.05 1000 1000 50.00 44.85
0.0098 10 1000 1000 50.00 38.66 0 2000 100.00 46.43
0.0000
H2O	
+HCl
1500 1500 50.00 39.28 500 500 50.00 48.03
Total 17500 6500 14500 8500
MIC	-	mcg/ml Parameters MIC	-	mcg/ml Parameters
0.5429
a -63.15
0.2792
a -163.03
b 39.28 b 48.03
Note:	A.i.	conc.	=	active	ingredient	concentration,	MIC	=	Minimum	inhibitory	concentration
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trend	for	the	strongyle	populations	obtained	from	
bisons	has	highlighted	as	through	EHA	revealed	a	
minimal	 risk	 for	MBZ	 (Y
max
	=	 -	860.66),	 followed	
by	TBZ	(Y
max
	=	-	773.34)	and	ABZ	(Y
max
		=	479.19).
LDA	 tests	 showed	 that	 the	 minimal	 risk	 of	
inducing	 resistance	 to	 anthelmintic	 medication 
was	registered	for	PYR	(Y
max
	=	-767.12),	followed	
by	TBZ,	MBZ	and	ABZ.	From	the	EC
50	
point	of	view,	
the	maximum	efficacy	was	 recorded	 in	MBZ	and	
TBZ,	the	last	being	ABZ	with	a	EC
50	
of	0.326	mcg/ml.	
However,	according	to	the	standard	interpretation	
of	this	test,	in	which	the	tested	parasite	population	
is	 considered	 to	 be	 resistant	 if	 the	 hatching	
percentage	 at	 the	 reference	 concentration	 (0.15	
mcg/ml)	is	higher	than	50%	(Cernea	et al.,	2015;	
Coles	et al.,	1992),	all	tested	benzimidazoles	have	
been	 shown	 to	 present	 hatching	 percentages	
as	 low	as	50%.	From	this	point	of	view,	 the	best	
efficacy	was	recorded	with	MBZ,	followed	by	TBZ	
and	ABZ.	Determination	of	MIC	for	the	four	tested	
anthelmintic	 substances,	 showed	 that	 the	 lower	MIC was	0.2144	mcg/ml	for	TBZ,	followed	by	PYR	
with	 0.2792	mcg/ml,	 MBZ	with	 0.5429	mcg/ml,	
the	last	being	ABZ	with	0.8187	mcg/ml.	As	for	the	
antiparasitic	 potency,	 TBZ	 and	PYR	had	 the	 best	
results,	folowed	by	MBZ	and	ABZ.	
The	 benzimidazole	 group	 efficacy	 results	
are	 similar	 to	 the	 ones	 obtained	 in	 other	 bison	
populations	 (Demiaszkiewicz	 et al.,	 2010).	 The	
results	 show	 that	 bison	 strongyle	 populations	
are	 still	 very	 sensitive	 to	 benzimidazoles	 and	
tetrahydropyrimidines,	totally	diferent,	compared	
to	 strongyle	 populations	 in	 horsers,	 which	
already	 developed	 a	 wide	 resistance	 against	
benzimidazoles,	especially	against	ABZ	(Cernea	et 
al.,	2015).
CONCLUSIONS
Both	 in vitro	 tests	 showed	 efficacy	 of	 the	
evaluated	antiparasitic	active	 ingredients	against	
strongyle	 population	 found	 in	 European	 bisons	
as	 well	 as	 a	 limited	 risk	 of	 inducing	 resistance	
phenomena.
It	may	be	advisable	to	use	MBZ-based	products	
(EC
50	
	-0.2270)	as	antiparasitic	medication	against	
nematodes	 for	 this	bison	population,	but	 subject	
to	 the	 fact	 that	 in vivo	 ABZ,	 due	 to	 its	 active	
metabolites,	 has	 a	 longer	 contact	 duration	 and	
efficacy	than	other	benzimidazoles.	
All	benzimidazoles	have	been	shown	to	have	
a	 hatching	 percentage	 much	 lower	 then	 50%,	
reflecting	 a	 lack	 of	 resistance	 against	 this	 drug	
class	for	the	tested	strongyle	population.
Even	 if	 tetrahydropyrimidines	 do	 not	
have	 ovicidal	 effects,	 they	 have	 shown	 a	 high	
antiparasitic	potency,	being	a	very	good	alternative	
in	case	of	benzimidazole	resistance.	
Acknowledgments.	 This	 research	 did	 not	
receive	any	specific	grant	from	funding	agencies	in	
the	public,	commercial,	or	not-for-profit	sectors.
REFERENCES
1.	 Cernea	 M,	 Cernea	 Cristina,	 Carvalho	 L	 (2010).	 Bio-
mathematical	 software	 applicable	 in	 pharmacological	
resistance	tests.	Scientia	Parasitologica,	11	(1):	24-28.
2.	 Cernea	 M,	 Cristina	 RT,	 Ştefănuţ	 Laura	 C,	 Madeira	 de	
Carvalho	 Luís	 M,	 Taulescu	 MA	 and	 Cozma	 V	 (2015).	
Screening	for	anthelmintic	resistance	in	equid	strongyles	
(Nematoda)	 in	 Romania.	 Folia	 Parasitologica,	 doi:	
10.14411/fp.2015.023.
3.	 Cernea	 M,	 Cozma	 V,	 Cernea	 Laura	 (2005).	 Detection	
of	 antihelmintic	 benzimidazole	 resistance	 in	 horse	
strongyles	 from	 North-West	 of	 Romania.	 Bulletin	 of	
University	 of	 Agricultural	 Sciences	 and	 Veterinary	
Medicine	Cluj-Napoca,	Veterinary	Medicine,	62:	56-62. 
4.	 Cernea	M,	 Cozma	 V,	 Cernea	 Cristina,	 Nueleanu	 Veturia, Mărculescu	 Anca,	 Onac	 Diana	 (2006).	 Effectiveness	 of	
benzimidazoles	 in	 treating	 Strongyloides	 in	 donkeys. 
Bulletin	 of	 University	 of	 Agricultural	 Sciences	 and	
Veterinary	 Medicine	 Cluj-Napoca,	 Veterinary	 Medicine,	
63:	49-53.
5.	 Coles	 GC,	 Bauer	 C,	 Borgsteede	 FHM,	 Geerts	 S,	 Klei	 TR,	
Taylor	MA,	Waller	 PJ	 (1992).	World	 Association	 for	 the	
Advancement	 of	 Veterinary	 Parasitology	 (W.A.A.V.P.)	
methods	 for	 the	 detection	 of	 anthelmintic	 resistance	 in	
nematodes	 of	 veterinary	 importance.	 Vet.	 Parasitol.,	 44	
(1-2):	35-44.
6.	 Demiaszkiewicz	AW,	Krzysiak	MK,	Pyziel	AM,	Kuligowska	
I,	Lachowicz	J	(2010).	Efficacy	of	anthelminthic	treatment	
of	 wild	 ruminants	 in	 European	 Bison	 Show	 Reserve	 in	
Białowieża	National	 Park.	 	 Życie	Weterynaryjne,	 85	 (6):	
532-534.	
7.	 Le	 Jambre	 LF,	 Southcott	 WH,	 Dash	 KM	 (1978).	
Effectiveness	 of	 broad	 spectrum	 anthelmintics	 against	
selected	 lines	 of	 Trichostrongylus	 columbriformis.	 Aust.	
Vet.	J.,	54:	570-574.
8.	 Krzysiak	MK,	 Demiaszkiewicz	 AW,	 Pyziel	 AM,	 Larska	M	
(2015).	Parasitological	monitoring	in	the	European	bison	
(Bison	bonasus)	breeding	 center	of	Bialowieza	National	
Park.	Medycyna	Weterynaryjna,	71	(12):	791-795.	
9.	 Woodbury	Murray	R,	Lewis	W	Roy	(2011). The	efficacy	of	
pour-on	ivermectin	in	bison	(Bison bison). Can Vet J., 52(5): 
531–533.
CĂTANĂ et al
